Please use this identifier to cite or link to this item:
Title: Carbapenemase Inhibitors: Updates on Developments in 2021
Authors: Zerdan, Maroun Bou
Hassan, Sally Al
Shaker, Waleed
Hajjar, Rayan El
Allam, Sabine
Zerdan, Morgan Bou
Naji, Amal
Zeineddine, Nabil
Affiliations: Faculty of Medicine 
Keywords: Carbapenem resistance
Carbapenemase inhibitors
Issue Date: 2022-07
Part of: Journal of Clinical Medicine Research
Volume: 14
Issue: 7
Start page: 251
End page: 259
Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avi-bactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbap-enemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance.
ISSN: 19183003
DOI: 10.14740/jocmr4764
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Dec 2, 2023

Record view(s)

checked on Dec 1, 2023

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.